RTI Surgical, a surgical implant company, has announced the first US implantation of its map3 cellular allogeneic bone graft in a foot and ankle procedure.
Map3 cellular allogeneic bone graft is based on Athersys’ licensed multipotent adult progenitor cell (MAPC) technology, which represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties.
Map3 is a natural and safe alternative to autograft and supplies the three elements necessary for bone repair – osteogenesis, osteoinduction and osteoconduction – in a single allograft.
RTI Surgical president and CEO Brian K Hutchison noted Dr Lyons’ successful use of map3 in a foot and ankle procedure is an exciting new development following its use in spine procedures.
"The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a limited market release of the implant later this year," added Hutchison.
To be available in various configurations and sizes, Map3 will provide bone grafting options for various bone repair, reconstruction and fusion procedures.